Who Exports Dapagliflozin from India — 254 Suppliers Behind a $49.5M Market
India's dapagliflozin export market is supplied by 254 active exporters who collectively shipped $49.5M across 5,104 shipments. AJANTA PHARMA LIMITED leads with a 17.1% market share, followed by MICRO LABS LIMITED and ALEMBIC PHARMACEUTICALS LIMITED. The top 5 suppliers together control 60.7% of total export value, reflecting a concentrated market structure.
Top Dapagliflozin Exporters from India — Ranked by Export Value
AJANTA PHARMA LIMITED is the leading dapagliflozin exporter from India, holding a 17.1% share of the $49.5M market across 5,104 shipments from 254 exporters. The top 5 suppliers — AJANTA PHARMA LIMITED, MICRO LABS LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, INVENTIA HEALTHCARE LIMITED, CIPLA LIMITED — collectively control 60.7% of total export value, indicating a moderately concentrated market. Individual shares are: AJANTA PHARMA LIMITED (17.1%), MICRO LABS LIMITED (15.5%), ALEMBIC PHARMACEUTICALS LIMITED (12.3%), INVENTIA HEALTHCARE LIMITED (9.3%), CIPLA LIMITED (6.6%).
Top Dapagliflozin Exporters from India
Ranked by export value · 254 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | AJANTA PHARMA LIMITED DAPAVEL 10MG 10 TAB DAPAGLIFLOZINDAPAGLIFLOZIN TABLET 10 MG [BULK PACK TADAPAGLIFLOZIN 10 MG AND METFORMIN HYDROC | $8.4M | 4 | 17.1% |
| 2 | MICRO LABS LIMITED DAPAVEL 10MG 10 TAB DAPAGLIFLOZINDAPAGLIFLOZIN TABLET 10 MG [BULK PACK TADAPAGLIFLOZIN 10 MG AND METFORMIN HYDROC | $7.7M | 24 | 15.5% |
| 3 | ALEMBIC PHARMACEUTICALS LIMITED DAPAGLIFLOZIN TAB 10MG 3X10T PMS_CNDAPAQUISDAPAGLIFLOZIN TABLETS 10 MG | $6.1M | 3 | 12.3% |
| 4 | INVENTIA HEALTHCARE LIMITED DAPAGLIFLOZIN TAB 10MG 3X10T PMS_CNDAPAGLIFLOZIN TABLETS 10 MGDAPAGLIFLOZIN TAB 10MG 100BT PMS_CN | $4.6M | 11 | 9.3% |
| 5 | CIPLA LIMITED DAPAQUISDAPAVEL 10MG 10 TAB DAPAGLIFLOZINFORXIGA 10MG 98 TAB DAPAGLIFLOZIN | $3.3M | 8 | 6.6% |
| 6 | MACLEODS PHARMACEUTICALS LTD | $2.7M | 8 | 5.5% |
| 7 | WATSON PHARMA PRIVATE LIMITED DAPAGLIFLOZIN TAB 10MG 3X10T PMS_CNDAPAGLIFLOZIN TABLETS 10 MGDAPAGLIFLOZIN TAB 10MG 100BT PMS_CN | $1.8M | 6 | 3.7% |
| 8 | HETERO LABS LIMITED DAPAGLIFLOZIN TABLETS 10MG PAFAZIN 10MG 150 SDAPAGLIFLOZIN 10MG 60X10 SUDAIR SAPAFAZIN 10MG 150'S | $1.2M | 11 | 2.5% |
| 9 | SANDOZ PRIVATE LIMITED DAPAGLIFLOZIN TAB 10MG 3X10T PMS_CNDAPAGLIFLOZIN TABLETS 10 MGDAPAGLIFLOZIN TAB 10MG 100BT PMS_CN | $1.1M | 3 | 2.3% |
| 10 | APL HEALTHCARE LIMITED DAPAGLIFLOZIN TAB 10MG 3X10T PMS_CNDAPAGLIFLOZIN TABLETS 10 MGDAPAGLIFLOZIN TAB 10MG 100BT PMS_CN | $1.0M | 2 | 2.1% |
| 11 | MSN LABORATORIES PRIVATE LIMITED DAPAGLIFLOZIN TABLETS 10MG PAFAZIN 10MG 150 SDAPAGLIFLOZIN 10MG 60X10 SUDAIR SAPAFAZIN 10MG 150'S | $825.0K | 8 | 1.7% |
| 12 | EXEMED PHARMACEUTICALS CATANIA DAPAGLIFLOZIN 10MG FILM-COATED TABLETGLYHARTDAJIO-10 - TAX INVOICE NO: 701209681 DT: 06.01.2025 | $775.4K | 2 | 1.6% |
| 13 | INNOVA CAPTAB LIMITED | $728.6K | 1 | 1.5% |
| 14 | AUROBINDO PHARMA LTD DAPAGLIFLOZIN TAB 10MG 3X10T PMS_CNDAPAGLIFLOZIN TABLETS 10 MGDAPAGLIFLOZIN TAB 10MG 100BT PMS_CN | $688.9K | 2 | 1.4% |
| 15 | SAVA HEALTHCARE LIMITED DAPAVEL 10MG 10 TAB DAPAGLIFLOZINFORXIGA 10MG 98 TAB DAPAGLIFLOZINDAPAGLIFLOZIN 10MG TAB- 10X10 BATCH NUMB | $681.6K | 2 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Dapagliflozin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Ajanta Pharma Limited | Not Listed | Yes (Inspection Date | Yes | Not Found | MHRA issued a GMP certificate to Ajanta Pharma's Paithan facility on 09/09/2013. |
| Alembic Pharmaceuticals Limited | Approved | Yes (Inspection Date | Yes | 223 (as of 2025) | Alembic Pharmaceuticals received multiple FDA approvals between 2024 and 2025, i |
| Inventia Healthcare Limited | Not Listed | Not Found | Yes | Not Found | MHRA issued a GMP certificate to Inventia Healthcare's Ambernath facility on 12/ |
| Micro Labs Limited | Not Listed | Not Found | Not Found | Not Found | No specific regulatory certifications found in the available data. |
| Cipla Limited | Approved | Not Found | Not Found | Not Found | Cipla Limited has received FDA approvals for various products; specific details |
| Macleods Pharmaceuticals Ltd | Approved | Not Found | Not Found | Not Found | Macleods Pharmaceuticals Ltd has received FDA approvals for various products; sp |
| Hetero Labs Limited | Approved | Not Found | Not Found | Not Found | Hetero Labs Limited has received FDA approvals for various products; specific de |
| Sandoz Private Limited | Approved | Not Found | Not Found | Not Found | Sandoz Private Limited has received FDA approvals for various products; specific |
| Aurobindo Pharma Ltd | Approved | Not Found | Not Found | Not Found | Aurobindo Pharma Ltd has received FDA approvals for various products; specific d |
| MSN Laboratories Private Limited | Approved | Not Found | Not Found | Not Found | MSN Laboratories Private Limited has received FDA approvals for various products |
TransData Nexus reviewed the regulatory standing of 10 leading Dapagliflozin exporters from India. 7 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 3 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Dapagliflozin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, particularly the Balanagar Industrial Area, is renowned for its production of Active Pharmaceutical Ingredients (APIs). Companies like Bio-Synth, established in 1943, operate WHO-GMP–certified facilities here, ensuring high-purity Dapagliflozin APIs that comply with global regulatory standards. The city's infrastructure supports large-scale API manufacturing, making it a critical hub for bulk drug production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant center for pharmaceutical formulations. Alembic Pharmaceuticals, headquartered in Vadodara, exemplifies this specialization. The company manufactures and markets pharmaceutical products, including APIs and formulations, and has a presence in the macrolide anti-infective drug segment. Alembic Pharmaceuticals produces formulations for therapeutic areas such as cardiology, dermatology, diabetes, ophthalmology, and infectious diseases for domestic and international markets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a crucial export gateway for pharmaceutical products. Cipla Limited, headquartered in Mumbai, is a prominent player in this area. The company has been involved in exporting Dapagliflozin tablets to various international markets, including Ghana. The region's well-developed port facilities and logistics infrastructure facilitate efficient global distribution of pharmaceutical products.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a pharmaceutical manufacturing hub, largely due to favorable tax incentives. This zone attracts numerous pharmaceutical companies seeking cost-effective production solutions. The region's growth underscores its strategic importance in India's pharmaceutical landscape.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Assess Regulatory Compliance: Prioritize suppliers with WHO-GMP and other relevant certifications to ensure product quality and compliance with international standards.
- Evaluate Export Capabilities: Partner with companies that have established export infrastructures, particularly those in the Mumbai-Thane-Raigad region, to facilitate seamless global distribution.
- Monitor Market Dynamics: Stay informed about regional developments, such as policy changes or infrastructure improvements, that could impact supplier performance and supply chain stability.
By strategically leveraging India's pharmaceutical clusters, companies can optimize their sourcing strategies for Dapagliflozin, ensuring a robust and reliable supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Dapagliflozin exporters from India
Alembic Pharmaceuticals Limited — Alembic Pharmaceuticals acquires 100% stake in Aleor Dermaceuticals
In March 2022, Alembic Pharmaceuticals Limited completed the acquisition of the remaining 40% stake in Aleor Dermaceuticals Ltd., making it a wholly-owned subsidiary. This move aimed to strengthen Alembic's position in the dermatology segment. IMPACT: The acquisition is expected to enhance Alembic's product portfolio, potentially increasing its Dapagliflozin exports.
Impact: The acquisition is expected to enhance Alembic's product portfolio, potentially increasing its Dapagliflozin exports.
Amneal Pharmaceuticals — Amneal Pharmaceuticals acquires Punishka Healthcare for Rs 700 crores
In November 2021, Amneal Pharmaceuticals acquired Punishka Healthcare, an injectable medicines manufacturer based near Ahmedabad, India. This acquisition expanded Amneal's manufacturing capacity for injectable products. IMPACT: While Amneal is not listed among the top Dapagliflozin exporters, this acquisition may influence the competitive landscape in the pharmaceutical export market.
Impact: While Amneal is not listed among the top Dapagliflozin exporters, this acquisition may influence the competitive landscape in the pharmaceutical export market.
Intas Pharmaceuticals — Intas Pharmaceuticals acquires Teva's UK & Ireland assets for $764 million
In 2016, Intas Pharmaceuticals acquired the UK and Ireland assets of Teva Pharmaceuticals for $764 million, aiming to strengthen its presence in the European market. IMPACT: Although this event occurred outside the specified 18-month period, it significantly enhanced Intas's export capabilities, potentially affecting Dapagliflozin exports.
Impact: Although this event occurred outside the specified 18-month period, it significantly enhanced Intas's export capabilities, potentially affecting Dapagliflozin exports.
Common Questions — Dapagliflozin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which dapagliflozin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, AJANTA PHARMA LIMITED leads with 103 recorded shipments worth $8.4M. MICRO LABS LIMITED (442 shipments) and ALEMBIC PHARMACEUTICALS LIMITED (95 shipments) are also established high-volume exporters.
Q How many dapagliflozin manufacturers are there in India?
India has 254 active dapagliflozin exporters with a combined export market of $49.5M across 5,104 shipments to 113 countries. The top 5 suppliers hold 60.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for dapagliflozin from India?
Average FOB unit price: $11.25 per unit, ranging from $0.01 to $2636.12. Average shipment value: $9.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 254 verified Indian exporters of Dapagliflozin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 5,104 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 113 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5,104 Verified Shipments
254 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists